Jun 19, 2013, 10.14 AM IST
Riluzole is indicated for treating amyotrophic lateral sclerosis and according to IMS Health data had sales of USD 64 million for year ended March 2013.
Like this story, share it with millions of investors on M3
Glenmark gets final US nod for sclerosis treatment drug
Riluzole is indicated for treating amyotrophic lateral sclerosis and according to IMS Health data had sales of USD 64 million for year ended March 2013.
Like this story, share it with millions of investors on M3
Glenmark gets final US nod for sclerosis treatment drug
Riluzole is indicated for treating amyotrophic lateral sclerosis and according to IMS Health data had sales of USD 64 million for year ended March 2013.
Pharma major Glenmark 's US generics arm has received final approval from the US Food and Drugs Administration to sell Riluzole tablets in 50 mg strength.
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis and Glenmark Generics Inc said it will start shipping the tablets immediately.
Riluzole had sales of USD 64 million for the year ended March 2013, the company said on Wednesday, citing IMS Health data.
Glenmark now has 86 products authorized for distribution in the US market and 52 ANDAs (abbreviated new drug applications) are pending approval with the country's drug regulator.
Glenmark shares were trading up a little over 1 percent at Rs 580 on NSE in morning trade.
From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'
The latest earning numbers FIRST on CNBC-TV18
Anda sedang membaca artikel tentang
Glenmark gets final US nod for sclerosis treatment drug
Dengan url
https://olahragakecantikan.blogspot.com/2013/06/glenmark-gets-final-us-nod-for.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Glenmark gets final US nod for sclerosis treatment drug
namun jangan lupa untuk meletakkan link
Glenmark gets final US nod for sclerosis treatment drug
sebagai sumbernya
0 komentar:
Posting Komentar